Infection risk in patients on multiple sclerosis therapeutics

CNS Drugs

Volumn 29, Issue 3, 2015, Pages 229-244

  Williamson, Eric M ^a   Berger, Joseph R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOLOGIC FACTOR;

HUMAN; INFECTION; MULTIPLE SCLEROSIS; PATHOPHYSIOLOGY; RISK;

HUMANS; IMMUNOLOGIC FACTORS; INFECTION; MULTIPLE SCLEROSIS; RISK;

EID: 84939995568     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-015-0226-2     Document Type: Review

References (150)

1. Weinshenker BG, Bass B, Rice GPA, et al. The natural history of multiple sclerosis: a geographically based study. I: clinical course and disability. Brain. 1989;112:133-46.
2. Polman CH, Reingold SC, Banwell B. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69:292-302.
3. Murta V, Ferrari CC. Influence of peripheral inflammation on the progression of multiple sclerosis: evidence from the clinic and experimental animal models. Mol Cell Neurosci. 2013;53:6-13.
4. Stadelmann C, Wegner C, Bruck W. Inflammation, demyelination, and degeneration: recent insights from MS pathology. Biochim Biophys Acta. 2011;1812:275-82.
5. Sospedra M, Martin R. Immunology of multiple sclerosis. Ann Rev Immunol. 2005;23:683-747.
6. Finsten B, Owens T. Innate immune responses in central nervous system inflammation. FEBS Lett. 2011;585(23):3806-12.
7. Esiri MM. Multiple sclerosis: a quantitative and qualitative study of immunoglobulin-containing cells in the central nervous system. Neuropathol Appl Neurobiol. 1980;6:9-21.
8. Wootla B, Denic A, Keegan BM, et al. Evidence for the role of B cells and immunoglobulins in the pathogenesis of multiple sclerosis. Neurol Res Int. 2011;2011:780712.
9. Cotran R, Kumar V, Tucker C. Robbins pathologic basis of disease. 6th ed. Philadelphia: WB Saunders; 1999. p. 1326.
10. Anthony DC, Couch Y, Losey P, Evans MC. The systemic response to brain injury and disease. Brain Behav Immun. 2012;26(4):534-40.
11. Sibley WA, Bamford CR, Clark K. Clinical viral infections and multiple sclerosis. Lancet. 1985;1:1313-5.
12. Andersen O, Lygner PE, Bergstrom T, et al. Viral infections trigger multiple sclerosis relapses: a prospective seroepidemiological study. J Neurol. 1993;240:417-22.
13. Buljevac D, Flach HZ, Hop WCJ, et al. Prospective study on the relation between infections and multiple sclerosis exacerbations. Brain. 2002;125:952-60.
14. Confavreux C. Infections and the risk of relapse in multiple sclerosis. Brain. 2002;125(5):933-4.
15. Coles AJ, Wing MG, Molyneux P, et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol. 1999;46:296-304.
16. Correale J, Fiol M, Gilmore W. The risk of relapses in multiple sclerosis during systemic infections. Neurology. 2006;67(4):652-9.
17. Edwards LJ, Sharrack B, Ismail A, et al. Central inflammation versus peripheral regulation in multiple sclerosis. J Neurol. 2011;258:1518-27.
18. Mikulkova Z, Praksova P, Stourac P, et al. Imbalance in T-cell and cytokine profiles in patients with relapsing-remitting multiple sclerosis. J Neurol Sci. 2011;300:135-41.
19. Trenova AG, Manova MG, Kostadinova II, et al. Clinical and laboratory study of pro-inflammatory and anti-inflammatory cytokines in women with multiple sclerosis. Folia Med (Plovdiv). 2011;53:29-35.
20. Ysrraelit MC, Gaitan MI, Lopez AS, Correale J. Impaired hypothalamic-pituitary-adrenal axis activity in patients with multiple sclerosis. Neurology. 2008;71:1948-54.
21. Hauser SL, Doolittle TH, Lincoln R, et al. Cytokine accumulations in CSF of multiple sclerosis patients: frequent detection of interleukin-1 and tumor necrosis factor but not interleukin-6. Neurology. 1990;40:1735-9.
22. Racke MK, Lovett-Racke AE, Karandikar NJ. The mechanism of action of glatiramer acetate treatment in multiple sclerosis. Neurology 2010;74(Suppl 1):S25-30.
23. Loma I, Heyman R. Multiple sclerosis: pathogenesis and treatment. Curr Neuropharmacol. 2011;9:409-16.
24. Pucci E, Giuliani G, Solari A, et al. Natalizumab for relapsing remitting multiple sclerosis. Cochrane Database Syst Rev. 2011;(10):CD007621.
25. Saidha S, Eckstein C, Calabresi PA. New and emerging disease modifying therapies for multiple sclerosis. Ann N Y Acad Sci. 2012;1247:117-37.
26. Brinkmann V, Pinschewer D, Chiba K, Feng L. FTY720: a novel transplantation drug that modulates lymphocyte traffic rather than activation. Trends Pharmacol Sci. 2000;21(2):49-52.
27. Chun J, Brinkmann V. A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya). Discov Med. 2011;12(64):213-28.
28. Gasperini C, Ruggieri S. New oral drugs for multiple sclerosis. Neurol Sci. 2009;30(Suppl 2):S179-83.
29. Gasperini C, Ruggieri S. Emerging oral drugs for relapsing-remitting multiple sclerosis. Expert Opin Emerg Drugs. 2011;16:697-712.
30. Gold R, Kappos L, Bar-Or A. Clinical efficacy of BG-12, an oral therapy, in relapsing remitting multiple sclerosis: data from the phase 3 DEFINE trial. Mult Scler J. 2011;17:S34.
31. Killestein J, Rudick RA, Polman CH. Oral treatment for multiple sclerosis. Lancet Neurol. 2011;10:1026-34.
32. Perry VH, Newman TA, Cunningham C. The impact of systemic infection on the progression of neurodegenerative disease. Nat Rev Neurosci. 2003;4:103-12.
33. Ransohoff R. Natalizumab and PML. Nat Neurosci. 2005;8:1275.
34. Berger JR. Progressive multifocal leukoencephalopathy and newer biological agents. Drug Saf. 2010;33:969-83.
35. Doerck S, Gobel K, Weise G, et al. Temporal pattern of ICAM-I mediated regulatory T cell recruitment to sites of inflammation in adoptive transfer model of multiple sclerosis. PLoS One. 2010;5:e15478.
36. Schweingruber N, Reichardt SD, Luhder F, Reichardt HM. Mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists. Mol Cell Endocrinol. 2007;24:174-82.
37. Cutolo MB, Seriolo C, Pizzorni ME, et al. Use of glucocorticoids and risk of infections. Autoimmun Rev. 2008;8(2):153-5.
38. Van Delden C. Infectious risks of immunomodulating therapies in rheumatology [in French]. Rev Med Suisse. 2006;2(57):738-40 (743-5).
39. Klein NC, Go CH, Cunha BA. Infections associated with steroid use. Infect Dis Clin North Am. 2001;15(2):423-32 (viii).
40. Stahn C, Lowenberg M, Homes DW, Buttgereit F. Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists. Mol Cell Endocrinol. 2007;275:71-8.
41. Spies CM, Biflsma JW, Burmester GR, Buttgereit F. Pharmacology of glucocorticoids in rheumatoid arthritis. Curr Opin Pharmacol. 2010;10:302-7.
42. Wiendl H, Toyka KV, Rieckmann P, Multiple Sclerosis Therapy Consensus Group. Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol. 2008;255:1449-63.
43. Johnson KP. Glatiramer acetate for treatment of relapsing-remitting multiple sclerosis. Expert Rev Neurother. 2012;12:371-84.
44. Karussis D. Immunotherapy of multiple sclerosis: the state of the art. Bio Drugs. 2013;27:113-48.
45. Winkelman A, Loebermann M, Reisinger EC, Zettl UK. Multiple sclerosis treatment and infectious issues: update. Clin Exp Immunol. 2014;175:425-38.
46. Fridkis-Hareli M, Strominger JL. Promiscuous binding of synthetic copolymer-1 to purified HLA-DR molecules. J Immunol. 1998;160:4386-97.
47. Ziemsen T, Kumpfel T, Klinkert WE, et al. Glatiramer acetate-specific T-helper 1-and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor. Brain. 2002;125:2381-91.
48. Hong J, Li N, Zhang X, et al. Induction of CD4+CD25+ regulatory T cells by copolymer-1 through activation of transcription factor Foxp3. Proc Natl Acad Sci. 2005;102:6449-54.
49. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1995;45:1268-76.
50. ®) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1998;50:701-8.
51. Marriott JJ, Miyasaki JM, Gronseth G, O'Connor PW, Therapeutics, Technology Assessment Subcommittee of the American Academy of Neurology. Evidence report: the efficacy and safety of mitoxantrone (Novantrone®) in the treatment of multiple sclerosis. Neurology. 2010;74:1463-70.
52. Martinelli V, Radaelli M, Straffi L, et al. Mitoxantrone: benefits and risks in multiple sclerosis patients. Neurol Sci. 2009;30(Suppl 2):S167-70.
53. Millefiorini E, Gasperini C, Pozzilli C, et al. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol. 1997;244(3):153-9.
54. Edan G, Miller D, Clanet M, et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry. 1997;62:112-8.
55. Hartung H, Gonsette R, Konig N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet. 2002;360(9350):2018-25.
56. Leger OJ, Yednock TA, Tanner L, et al. Humanization of a mouse antibody against human alpha-4- integrin: a potential therapeutic for the treatment of multiple sclerosis. Hum Antibodies. 1997;8:3-16.
57. ® prescribing information and safety update. Available at: https://medinfo.biogenidec.com/. Accessed 2 Mar 2015.
58. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med. 2005;353:369-74.
59. Langer-Gould A, Atlas SW, Green AJ, et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med. 2005;353:375-81.
60. Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med. 2005;353:362-8.
61. Brooks BR, Walker DL. Progressive multifocal leukoencephalopathy. Neurol Clin. 1984;2(2):299-313.
62. Berger J, Pall L, Lanska D, Whiteman M. Progressive multifocal leukoencephalopathy in patients with HIV infection. J Neurovirol. 1998;4(1):59-66.
63. Astrom KE, Mancall EL, Richardson EP Jr. Progressive multifocal leukoencephalopathy: a hitherto unrecognized complication of chronic lymphatic leukemia and Hodgkin's disease. Brain. 1958;81:93-111.
64. Berger J, Aksamit MD, Clifford D, et al. PML diagnostic criteria consensus statement from the AAN Neuroinfectious Disease Section. Neurology. 2013;80:1430-8.
65. Berger J, Khalili K. The pathogenesis of progressive multifocal leukoencephalopathy. Discov Med. 2011;12(67):495-503.
66. Bechtel M, Sanders C, Bechtel A. Neurological complications of biologic therapy in psoriasis: a review. J Clin Aesthet Dermatol. 2009;2(11):27-32.
67. Grinyo J, Charpentier B, Medina J, et al. An integrated safety profile analysis of belatacept in kidney transplant recipients. Transplantation. 2010;90(12):1521-7.
68. Nived O, Bengtsson AA, Jonsen A, Sturfelt G. Progressive multifocal leukoencephalopathy: the importance of early diagnosis illustrated in four cases. Lupus. 2008;17(11):1036-41.
69. Kothary N, Diak I, Brinker A, et al. Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients. J Am Acad Dermatol. 2011;65:546-51.
70. Waggoner J, Martinu T, Palmer S. Progressive multifocal leukoencephalopathy following heightened immunosuppression after lung transplant. J Heart Lung Transplant. 2009;28:395-8.
71. Neff RT, Hurst FP, Falta EM, et al. Progressive multifocal leukoencephalopathy and use of mycophenolate mofetil after kidney transplantation. Transplantation. 2008;86(10):1474-8.
72. Gonzalez H, Bolgert F, Camporo P, Leblond V. Progressive multifocal leukoencephalitis (PML) in three patients treated with standard-dose fludarabine (FAMP). Hematol Cell Ther. 1999;41:183-6.
73. Leonard S, Hulin C, Anxionnat R, et al. Multifocal progressive leukoencephalitis in a patient given fludarabine for chronic lymphoid leukemia [in French]. Rev Neurol (Paris). 2002;158:1121-3.
74. Saumoy M, Castells G, Escoda L, et al. Progressive multifocal leukoencephalopathy in chronic lymphocytic leukemia after treatment with fludarabine. Leuk Lymphoma. 2002;43:433-6.
75. Lejniece S, Murovska M, Chapenko S, et al. Progressive multifocal leukoencephalopathy following fludarabine treatment in a chronic lymphocytic leukemia patient. Exp Oncol. 2011;33:239-41.
76. Warnatz K, Peter HH, Schumacher M, et al. Infectious CNS disease as a differential diagnosis in systemic rheumatic diseases: three case reports and a review of the literature. Ann Rheum Dis. 2003;62(1):50-7.
77. Rahmlow M, Shuster E, Domnik J, et al. Leflunomide-associated progressive multifocal leukoencephalopathy. Arch Neurol. 2008;65(11):1538-9.
78. Ermis U, Wiesmann M, Nolte K, et al. Fumaric acid-associated progressive multifocal leukencephalopathy (PML), treatment and survival in a patient with psoriasis [abstract no. 84]. In: Presented at Kongress der Deutschen Gesellschaft fur Neurologie mit Fortbidlunsakademie. Nurnberg; 2011.
79. Van Oosten B, Killestein J, Barkhof F, et al. PML in a patient treated with dimethyl fumarate from a compounding pharmacy. N Engl J Med. 2013;368:17.
80. ® package insert. http://www.tecfidera.com/pdfs/full-prescribing-information.pdf. Accessed 25 Jan 2015.
81. Zaheer F, Berger J. Treatment-related progressive multifocal leukoencephalopathy: current understanding and future steps. Ther Adv Drug Saf. 2012;3(5):227-39.
82. Kappos L, Bates D, Hartung H, et al. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol. 2007;6:431-41.
83. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2013;366:1870.
84. Fine AJ, Sorbello A, Kortepeter C, Scarazzini L. Central nervous system herpes simplex and varicella zoster virus infections in natalizumab-treated patients. Clin Infect Dis. 2013;57(6):849-52.
85. Bourdette D, Gilden D. Fingolimod and multiple sclerosis: four cautionary tales. Neurology. 2012;79(19):1942-3.
86. Yeung J, Cauquil C, Saliou G, et al. Varicella-zoster virus acute myelitis in a patient with MS treated with natalizumab. Neurology. 2013;80(19):1812-3.
87. Bourre B, Lefaucheur R, Ahtoy P, et al. Varicella-zoster virus acute myelitis in a patient with MS treated with natalizumab. Neurology. 2013;81(22):1966-7.
88. Kwiatkowski A, Gallois J, Bilbault N, et al. Herpes encephalitis during natalizumab treatment in multiple sclerosis. Mult Scler. 2012;18(6):909-11.
89. Shenoy ES, Mylonakis E, Hurtado RM, Venna N. Natalizumab and HSV meningitis. J Neurovirol. 2011;17(3):288-90.
90. Fragoso YD, Brooks JB, Gomes S, de Oliveira FT, da Gama PD. Report of three cases of herpes zoster during treatment with natalizumab. CNS Neurosci Ther. 2013;19(4):280-1.
91. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358(7):676-8.
92. Hawker K, O'Connor P, Freedman MS, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol. 2009;66:460-71.
93. Lanini S, Molloy AC, Fine PE, et al. Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis. BMC Med. 2011;9:36.
94. Carbone J, del Pozo N, Gallego A, Sarmiento E. Immunological risk factors for infection after immunosuppressive and biologic therapies. Expert Rev Anti Infect Ther. 2011;9:405-13.
95. Molloy E, Calabrese L. Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk? Autoimmun Rev. 2008;8:144-6.
96. Carson K, Evens A, Richey E, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood. 2009;113:4834-40.
97. Genentech Personal Communication. San Francisco: July 18, 2014.
98. Fox EJ. Alemtuzumab in the treatment of relapsing-remitting multiple sclerosis. Expert Rev Neurother. 2010;10(12):1789-97.
99. Klotz L, Meuth S, Wiendl H. Immune mechanisms of new therapeutic strategies in multiple sclerosis: a focus on alemtuzumab. Clin Immunol. 2012;142:25-30.
100. Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomized controlled phase 3 trial. Lancet. 2012;380:1819-28.
101. Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomized controlled phase 3 trial. Lancet. 2012;380:1829-39.
102. ® package insert. http://www.tecfidera.com/pdfs/full-prescribing-information.pdf. Accessed 6 Feb 2015.
103. Martin S, Mart F, Fiumara K, et al. Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis. 2006;43:16-24.
104. O'Sullivan C, Dev KK. The structure and function of the S1P1 receptor. Trends Pharmaco Sci. 2013;34(7):401-12.
105. Cohen JA, Chun J. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis. Ann Neurol. 2011;69:759-77.
106. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362:387-401.
107. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362:402-15.
108. Uccelli A, Ginocchio F, Mancardi GL, Bassetti M. Primary varicella zoster infection associated with fingolimod treatment. Neurology. 2011;76(11):1023-4.
109. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387-401.
110. Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med. 2006;355:1124-40.
111. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):402-15.
112. Francis G, Kappos L, O'Connor P, et al. Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy. Mult Scler. 2014;20(4):471-80.
113. Berger JR. Varicella vaccination after fingolimod: a case report. Mult Scler Related Dis. 2013;2:391-4.
114. Ferraro D, De Biasi S, Vitetta F, et al. Recurrent varicella following steroids and fingolimod in a multiple sclerosis patient. J Neuroimmune Pharmacol. 2014;8(5):1059-61.
115. Ratchford JN, Costello K, Reich DS, Calabresi PA. Varicella-zoster virus encephalitis and vasculopathy in a patient treated with fingolimod. Neurology. 2013;81(3):306.
116. Kern RZ. Dear healthcare Provider. East hanover, NJ: Novartis (E-mail 17 Feb 2015).
117. Fox RI, Herrmann ML, Frangou CG, et al. Mechanism of action for leflunomide in rheumatoid arthritis. Clin Immunol. 1999;93:198-208.
118. O'Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011;365:1293-303.
119. Jenks KA, Stamp LK, O'Donnell JL, et al. Leflunomide-associated infections in rheumatoid arthritis. J Rheumatol. 2007;34(11):2201-3.
120. O'Connor PW, Li D, Freedman MS, et al. A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology. 2006;66:894-900.
121. Confavreux C, Li DK, Freedman MS, et al. Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years. Mult Scler. 2012;18:1278-89.
122. Treumer F, Zhu K, Glaser R, Mrowietz U. Dimethylfumarate is a potent inducer of apoptosis in human T cells. J Invest Dermatol. 2003;121:1383-8.
123. Stoof T, Flier J, Sampat S, et al. The antipsoriatic drug dimethylfumarate strongly suppresses chemokine production in human keratinocytes and peripheral blood mononuclear cells. Br J Dermatol. 2001;144:1114-20.
124. Gold R, Linker RA, Stangel M. Fumaric acid and its esters: an emerging treatment for multiple sclerosis with antioxidative mechanism of action. Clin Immunol. 2012;142:44-8.
125. Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367:1098-107.
126. Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367:1087-97.
127. Ermis U, Weis J, Schulz JB. PML in a patient treated with fumaric acid. N Engl J Med. 2013;368:1657-8.
128. Sweetser MT, Dawson KT, Bozic C. Manufacturer's response to case reports of PML. N Engl J Med. 2013;368:1659-61.
129. Bundesinstitut Fur Arzneimittel Und Medizinprodukte (BfArM) [Federal Institute for Drugs and Medical Devices]. Adverse events database 2013. http://www.bfarm.de/DE/Pharmakovigilanz/uaw-db-node.html. Accessed 8 Aug 2013.
130. Keating M, Kantarjian H, Talpaz M, et al. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood. 1989;74:19-25.
131. Sipe J. Cladribine for multiple sclerosis: review and current status. Expert Rev Neurother. 2005;5(6):721-7.
132. Sipe J. Cladribine tablets: a potential new short-course annual treatment for relapsing multiple sclerosis. Expert Rev Neurother. 2010;10(3):365-75.
133. Giacomini PS, Bar-Or A. Laquinimod in multiple sclerosis. Clin Immunol. 2012;142(1):38-43.
134. Bruck W, Wegner C. Insight into the mechanism of laquinimod action. J Neurol Sci. 2011;306:173-9.
135. Brunmark C, Runstrom A, Ohlsson L, et al. The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. J Neuroimmunol. 2002;130:163-72.
136. Gurevich M, Gritzman T, Orbach R, et al. Laquinimod suppress antigen presentation in relapsing- remitting multiple sclerosis: in-vitro high-throughput gene expression study. J Neuroimmunol. 2010;221(1-2):87-94.
137. Polman C, Barkhof F, Sandberg-Wollheim M, et al. Laquinimod in relapsing MS. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology. 2005;64:987-91.
138. Comi G, Pulizzi A, Rovaris M, et al. Effect of laquinimod on MRI monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomized, double-blind, placebo-controlled phase IIb study. Lancet. 2008;371:2085-92.
139. Comi G, Abramsky O, Arbizu T, et al. Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel group placebo-controlled study. Mult Scler. 2010;16:1360-6.
140. Comi G, Jeffery D, Kappos L, et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med. 2012;366:1000-9.
141. Tony HP, Burmester G, Schulze-Koops H, et al. Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res Ther. 2011;13:R75.
142. Bielekova B, Howard T, Packer AN, et al. Effect of Anti-CD25 Antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch Neurol. 2009;66(4):483-9.
143. Bielekova B. Daclizumab therapy for multiple sclerosis. Neurotherapeutics. 2013;10:55-67.
144. Rose JW, Burns JB, Bjorklund J, et al. Daclizumab phase II trial in relapsing and remitting multiple sclerosis. Neurology. 2007;69(8):785-9.
145. Wynn D, Kaufman M, Montalban X, et al. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomized double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol. 2010;9:381-90.
146. Liu J, Wang L, Zhan SY, Xia Y. Daclizumab for relapsing remitting multiple sclerosis. Cochrane Database Syst Rev. 2012; (4): CD008127.
147. Gold R, Giovannoni G, Selmaj K, et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomized, double-blind, placebo-controlled trial. Lancet. 2013;381:2167-75.
148. Ryschkewitsch CF, Jensen PN, Monaco MC, Major EO. JC virus persistence following progressive multifocal leukoencephalopathy in multiple sclerosis patients treated with natalizumab. Ann Neurol. 2010;68:384-91.
149. Plavina T, Subramanyam M, Bloomgren G, et al. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol. 2014;76:802-12.
150. Winkelman A, Loebermann M, Reisinger EC, et al. Fingolimod treatment for multiple sclerosis patients. What do we do with varicella? Ann Neurol. 2011;70:673-4 (author reply 4).